BriaCell Therapeutics (BriaCell Therapeutics) Inventory-to-Revenue : 0.00 (As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BriaCell Therapeutics's Average Total Inventories for the quarter that ended in Jan. 2024 was $0.00 Mil. BriaCell Therapeutics's Revenue for the three months ended in Jan. 2024 was $0.00 Mil.

BriaCell Therapeutics's Inventory-to-Revenue for the quarter that ended in Jan. 2024 stayed the same from Oct. 2023 (0.00) to Oct. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

BriaCell Therapeutics Inventory-to-Revenue Historical Data

The historical data trend for BriaCell Therapeutics's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Inventory-to-Revenue Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Inventory-to-Revenue

Get a 7-Day Free Trial

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BriaCell Therapeutics's Inventory-to-Revenue

For the Biotechnology subindustry, BriaCell Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Inventory-to-Revenue falls into.

BriaCell Therapeutics Inventory-to-Revenue Calculation

BriaCell Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Jul. 2023 is calculated as

	Inventory-to-Revenue (A: Jul. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Jul. 2022 )	+	Total Inventories (A: Jul. 2023 ))	/	count )	/	Revenue (A: Jul. 2023 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=	N/A

BriaCell Therapeutics's Inventory-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

	Inventory-to-Revenue (Q: Jan. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Oct. 2023 )	+	Total Inventories (Q: Jan. 2024 ))	/	count )	/	Revenue (Q: Jan. 2024 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

BriaCell Therapeutics (NAS:BCTX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BriaCell Therapeutics's Days Inventory for the three months ended in Jan. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jan. 2024 )	/	Cost of Goods Sold (Q: Jan. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BriaCell Therapeutics's Inventory Turnover for the quarter that ended in Jan. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jan. 2024 )	/	Average Total Inventories (Q: Jan. 2024 )
	=	0	/	0
	=

BriaCell Therapeutics Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

BCT:Canada

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Executives

Jamieson Bondarenko	director	402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub	director	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin	officer: CFO & Secretary	MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del	officer: Chief Medical Officer	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams	director, officer: President & CEO	620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg	director	201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago	officer: Chief Scientific Officer	2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony	director	P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig	director	4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3